PROTANBIO is leading the life sciences
with world-class technology and research,
aiming to stand as a global bio-company
Thank you for visiting PROTANBIO. Discovered the world's first blood-based
diagnostic markers for lung cancer
CEO Je-Yoel Cho   
  • Career - Professor, Department of Biochemistry, College of
       Veterinary Medicine, Seoul National University
    - President, The Korean Society of Proteomics
    - Director of Current World Proteome Society
    - Chairperson, Asian Oceanic Proteome Society Organization
    - Former chairman, The Korean Society of Biochemistry and
       Molecular Biology
  • Education 1989 BA Seoul National University, Department of Veterinary Medicine
    1991 MA Seoul National University, Department of Veterinary Medicine
    1995 MA Ohio State University
    1999 PhD Ohio State University
    1999-2000 PostDoc Ohio State University
    2001-2003 PostDoc Harvard university
PROTANBIO is currently represented by Je-Yoel Cho, a professor of Seoul National University, College of Veterinary Medicine and a Chairman of the Korea Proteomics Society. PROTANBIO is a venture company of Seoul National University aming to establish protein markers utilizing proteomics. With our expertise, we are discovering new diagnostic markers for various diseases, ranging from lung cancer and breast cancer to mental illness using blood samples. Research experience over 15 years has led us to the most number of patents regarding domestic lung cancer biomarkers. In addition, PROTANBIO has developed lung cancer diagnostic kit that can detect early stages of lung cancer in an efficient and cost-effective method via blood. Simultaneously, we are developing Kit for an early diagnosis of mental illness and brain injuries. Recently, with our antibody technology, we have been expanding our research into the development of anti-cancer drugs such as CAR-T. We aim to become a globally established bio-company that values technology and innovation to prepare for the future. Thank you.
  • 2021
    • MFDS Export license Approval of PROTAN COVID-19 IgG Type2
    • CE certification of PROTAN COVID-19 IgG Type2
  • 2020
    • CE certification of PROTAN COVID-19 IgM/IgG
    • Approval Export License of PROTAN COVID-19 IgM/IgG by MFDS
    • ISO13485:2016 certification
    • Approval PROTANVET Canine CRP Diagnostic kit by APQA
  • 2019
    • Attract Investment (Series B)
    • Wins the Grand Award of '2019 4IR Awards’
    • Approval of ‘Protan-SAA’ medical device by MFDS
    • PRO G-Reader 100’ authorized to manufacture veterinary medical devices
    • PRO G-Reader 100’ authorized to manufacture medical devices
    • 1 KFDA approval, 1 QIA approval, 2 trademark registrations
    • Technology transfers from Seoul National University (8 domestic and 2 international)
    • IP R&D supported and various other governmental projects
    • Expansion of 2nd laboratory
  • 2018
    • 1 trademark registration
    • GMP Certification
    • Relocation of HQ and company affiliated research institute(Seoul National University Biotechnology Research Center)
    • KFDA Approval of medical devices for export
    • Attract investment (primary) from LB Inv.
  • 2014
    • Selected by the Ministry of Commerce, Industry and Energy as “ Excellent innovation and performance in national R&D fund”
    • Finalize material transfer contract with Nanotech
    • Relocation in Seoul National University(the Institute of Molecular Biology & Genetics)
  • 2011
    • Finalize material transfer contract with Ubiomed Co., Ltd.
    • International publicity (RSC, ACS)
    • Expansion of Business Incubator
    • Establishment of the affiliated research institute
  • 2007
    • Technology Transfer from Kyungpook National University
    • Establishment PROTANBIO Co., Ltd.
    • Memorandum of understanding with SD Corporation
    • Awarded as Korea’s Business Executive for Venture Businesses by The Herald Business
    • Venture certification by Small and Medium Business Administration
    • Establishment of the company (Private)
Patent registration and application status
20 registrations and 2 applications
in lung cancer and cancer-related field
Various networks
including domestic and global medical institutions
  • Domestic network
    Seoul National University Hospital
    Seoul National University Bundang Hospital
    National Cancer Center
    Samsung Medical Center
    Asan Medical Center
    Kyungpook National University Hospital
    Kyungpook National University Chilgok Hospital
  • Global network
    Moncton, Canada, Canadian Health solutions
    Halifax, Canada, Dalhousie University Hospital
    Broad Institute of MIT and Harvard
    Sao Paolo, Brazil General Hospital
    Qatar Medical Pharma
    Middle East GCC (Middle East Gulf Region : Saudi
    Arabia, UAE, Qatar, Kuwait, Oman, Bahrein)
    MENA Region and Africa Region
    Osaka Prefecture University
CONTACT Main number Tel  02-3285-1413
Sales Team: +82 70-4112-2704
Fax 02-3285-1417
E-mail [email protected]